Aggressive drug marketing may endanger people: study

By Maggie Fox, Health and Science Editor

WASHINGTON (Reuters) - Quicker drug approvals and sophisticated marketing campaigns may be putting more patients at risk of dangerous side-effects but the same techniques might be put to use to protect them, a researcher argued on Tuesday.

New U.S. Food and Drug Administration procedures have clearly sped up some drug approvals, said Dr. David Kao of the University of Colorado Health Sciences Center.

For example, Merck & Co Inc’s anti-inflammatory drug Vioxx, or rofecoxib, had been tried by 20 million patients before it was withdrawn in 2004 because of its heart dangers.

Writing in the British Medical Journal, Kao said the 1992 Prescription Drug User Fee Act, or PDUFA, which authorizes fees from companies to beef up the FDA and speed drug approvals, cut the time needed to review a new drug from 33.6 months during 1979-86 to 16 months by the 1997-2002 period.

The revenue from the fees accounts for 43 percent of the FDA budget for drug oversight. Similar fees make up 75 percent of the funding for the European Agency for the Evaluation of Medicinal Products and all of Britain’s Medicines and Healthcare Products Regulatory Agency funding.

“It’s probably not helping drug safety,” Kao said in a telephone interview.

The closer to deadline that a new drug is approved, the more likely it is to later need strong safety warnings or to be withdrawn, he noted.


But drug companies may have the answer.

“I think the pharma companies are using ingenious methods of marketing,” Kao said. “And I think that the infrastructure is already there and we can capitalize on it to improve drug safety.”

New drugs are usually tested on a few thousand people at most, with rarer side-effects becoming evident only when they are used in the wider population. Watching for these effects is called post-approval surveillance.

“We just have very poor post-approval surveillance now,” Kao said. “People are going to want new drugs and it is going to be impossible to guarantee their safety before a lot of people get them.”

Companies could use multimedia techniques now used to sell their drugs to help patients watch for dangers, Kao said.

He cited the example of Merck’s Januvia, or sitagliptin, a diabetes drug.

“The FDA approved sitagliptin 3.8 years after the drug’s discovery; this compares with five years for rofecoxib and an industry average of 14.2 years between 1990 and 1999,” Kao wrote.  Continued…


Related Posts:

WASHINGTON (Reuters) - U.S. regulators issued guidelines on Monday that make it easier for drug companies and medical device makers to advise doctors about unapproved uses of their products. The Food and Drug Administration finalized a proposal issued in February 2008 that lets companies distribute medical journal articles describing unapproved uses. By law, manufacturers are prohibited from

Full Post: FDA lets drugmakers advise doctors on unapproved uses

By Lisa Richwine WASHINGTON (Reuters) - U.S. regulators remain concerned about serious risks from a class of asthma drugs and will ask U.S. advisers next week if approval for treating the lung disease should be revoked, documents released on Friday said. Staff in the Food and Drug Administration’s drug-safety office unanimously recommended withdrawing the approval of all

Full Post: FDA sees asthma drug risks

NEW YORK (Reuters) - The rise of serious heart risks in drugs that treat chronic conditions has become one of the U.S. Food and Drug Administration’s top worries and is changing how the agency weighs new medicines, a top FDA official said on Tuesday. The agency is thinking about how to weigh such possible side effects

Full Post: Drugs’ heart risk is FDA’s biggest worry: official

By Lisa Richwine WASHINGTON (Reuters) - A key Democrat made a renewed call on Monday for giving regulators the power to ban advertisements to consumers when a new medicine first reaches the market and risks are not fully known. Rep. Henry Waxman listed the idea as one of many he would like to pursue as chairman of

Full Post: Democrat backs advertising limits for medicines

NEW YORK (Reuters) - New data do not signal any heart risks with Takeda Pharmaceutical Co Ltd’s experimental drug to treat acid build-up in patients with gout, a top U.S. Food and Drug Administration official said in a document released on Thursday. Takeda is seeking U.S. approval to sell its drug febuxostat for chronic gout patients

Full Post: No heart risk seen with Takeda gout drug: FDA

Site Navigation

Most Read